These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

454 related articles for article (PubMed ID: 20014456)

  • 1. TRAIL-induced apoptosis of hepatocellular carcinoma cells is augmented by targeted therapies.
    Koehler BC; Urbanik T; Vick B; Boger RJ; Heeger S; Galle PR; Schuchmann M; Schulze-Bergkamen H
    World J Gastroenterol; 2009 Dec; 15(47):5924-35. PubMed ID: 20014456
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Suppression of Mcl-1 via RNA interference sensitizes human hepatocellular carcinoma cells towards apoptosis induction.
    Schulze-Bergkamen H; Fleischer B; Schuchmann M; Weber A; Weinmann A; Krammer PH; Galle PR
    BMC Cancer; 2006 Oct; 6():232. PubMed ID: 17014711
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bcl-x(L) and Myeloid cell leukaemia-1 contribute to apoptosis resistance of colorectal cancer cells.
    Schulze-Bergkamen H; Ehrenberg R; Hickmann L; Vick B; Urbanik T; Schimanski CC; Berger MR; Schad A; Weber A; Heeger S; Galle PR; Moehler M
    World J Gastroenterol; 2008 Jun; 14(24):3829-40. PubMed ID: 18609706
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The cyclin-dependent kinase inhibitor flavopiridol sensitizes human hepatocellular carcinoma cells to TRAIL-induced apoptosis.
    Miyashita K; Shiraki K; Fuke H; Inoue T; Yamanaka Y; Yamaguchi Y; Yamamoto N; Ito K; Sugimoto K; Nakano T
    Int J Mol Med; 2006 Aug; 18(2):249-56. PubMed ID: 16820931
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mcl-1 as a buffer for proapoptotic Bcl-2 family members during TRAIL-induced apoptosis: a mechanistic basis for sorafenib (Bay 43-9006)-induced TRAIL sensitization.
    Meng XW; Lee SH; Dai H; Loegering D; Yu C; Flatten K; Schneider P; Dai NT; Kumar SK; Smith BD; Karp JE; Adjei AA; Kaufmann SH
    J Biol Chem; 2007 Oct; 282(41):29831-46. PubMed ID: 17698840
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The regulatory protein GADD34 inhibits TRAIL-induced apoptosis via TRAF6/ERK-dependent stabilization of myeloid cell leukemia 1 in liver cancer cells.
    Song P; Yang S; Hua H; Zhang H; Kong Q; Wang J; Luo T; Jiang Y
    J Biol Chem; 2019 Apr; 294(15):5945-5955. PubMed ID: 30782845
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mcl-1 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in human cholangiocarcinoma cells.
    Taniai M; Grambihler A; Higuchi H; Werneburg N; Bronk SF; Farrugia DJ; Kaufmann SH; Gores GJ
    Cancer Res; 2004 May; 64(10):3517-24. PubMed ID: 15150106
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dovitinib sensitizes hepatocellular carcinoma cells to TRAIL and tigatuzumab, a novel anti-DR5 antibody, through SHP-1-dependent inhibition of STAT3.
    Chen KF; Chen HL; Liu CY; Tai WT; Ichikawa K; Chen PJ; Cheng AL
    Biochem Pharmacol; 2012 Mar; 83(6):769-77. PubMed ID: 22230479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ibulocydine sensitizes human hepatocellular carcinoma cells to TRAIL-induced apoptosis via calpain-mediated Bax cleavage.
    Park SS; Jwa E; Shin SH; Ju EJ; Park I; Pak JH; Hwang JJ; Cho DH; Kim BM; Kim SB; Lee JS; Song SY; Jeong SY; Choi EK
    Int J Biochem Cell Biol; 2017 Feb; 83():47-55. PubMed ID: 27923747
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced caspase-8 recruitment to and activation at the DISC is critical for sensitisation of human hepatocellular carcinoma cells to TRAIL-induced apoptosis by chemotherapeutic drugs.
    Ganten TM; Haas TL; Sykora J; Stahl H; Sprick MR; Fas SC; Krueger A; Weigand MA; Grosse-Wilde A; Stremmel W; Krammer PH; Walczak H
    Cell Death Differ; 2004 Jul; 11 Suppl 1():S86-96. PubMed ID: 15105837
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Partial contribution of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/TRAIL receptor pathway to antitumor effects of interferon-alpha/5-fluorouracil against Hepatocellular Carcinoma.
    Yamamoto T; Nagano H; Sakon M; Wada H; Eguchi H; Kondo M; Damdinsuren B; Ota H; Nakamura M; Wada H; Marubashi S; Miyamoto A; Dono K; Umeshita K; Nakamori S; Yagita H; Monden M
    Clin Cancer Res; 2004 Dec; 10(23):7884-95. PubMed ID: 15585621
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The proteasome inhibitor MG132 potentiates TRAIL receptor agonist-induced apoptosis by stabilizing tBid and Bik in human head and neck squamous cell carcinoma cells.
    Sung ES; Park KJ; Choi HJ; Kim CH; Kim YS
    Exp Cell Res; 2012 Aug; 318(13):1564-76. PubMed ID: 22513214
    [TBL] [Abstract][Full Text] [Related]  

  • 13. COX-2 inhibitors sensitize human hepatocellular carcinoma cells to TRAIL-induced apoptosis.
    Yamanaka Y; Shiraki K; Inoue T; Miyashita K; Fuke H; Yamaguchi Y; Yamamoto N; Ito K; Sugimoto K; Nakano T
    Int J Mol Med; 2006 Jul; 18(1):41-7. PubMed ID: 16786154
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quinacrine sensitizes hepatocellular carcinoma cells to TRAIL and chemotherapeutic agents.
    Wang W; Gallant JN; Katz SI; Dolloff NG; Smith CD; Abdulghani J; Allen JE; Dicker DT; Hong B; Navaraj A; El-Deiry WS
    Cancer Biol Ther; 2011 Aug; 12(3):229-38. PubMed ID: 21725212
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Bcl-xL inhibitor, ABT-737, efficiently induces apoptosis and suppresses growth of hepatoma cells in combination with sorafenib.
    Hikita H; Takehara T; Shimizu S; Kodama T; Shigekawa M; Iwase K; Hosui A; Miyagi T; Tatsumi T; Ishida H; Li W; Kanto T; Hiramatsu N; Hayashi N
    Hepatology; 2010 Oct; 52(4):1310-21. PubMed ID: 20799354
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bortezomib overcomes tumor necrosis factor-related apoptosis-inducing ligand resistance in hepatocellular carcinoma cells in part through the inhibition of the phosphatidylinositol 3-kinase/Akt pathway.
    Chen KF; Yeh PY; Hsu C; Hsu CH; Lu YS; Hsieh HP; Chen PJ; Cheng AL
    J Biol Chem; 2009 Apr; 284(17):11121-33. PubMed ID: 19261616
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BH3-only protein expression determines hepatocellular carcinoma response to sorafenib-based treatment.
    Busche S; John K; Wandrer F; Vondran FWR; Lehmann U; Wedemeyer H; Essmann F; Schulze-Osthoff K; Bantel H
    Cell Death Dis; 2021 Jul; 12(8):736. PubMed ID: 34312366
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytosolic and nuclear caspase-8 have opposite impact on survival after liver resection for hepatocellular carcinoma.
    Koschny R; Brost S; Hinz U; Sykora J; Batke EM; Singer S; Breuhahn K; Stremmel W; Walczak H; Schemmer P; Schirmacher P; Ganten TM
    BMC Cancer; 2013 Nov; 13():532. PubMed ID: 24209510
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sensitization of TRAIL-induced cell death by 20(S)-ginsenoside Rg3 via CHOP-mediated DR5 upregulation in human hepatocellular carcinoma cells.
    Lee JY; Jung KH; Morgan MJ; Kang YR; Lee HS; Koo GB; Hong SS; Kwon SW; Kim YS
    Mol Cancer Ther; 2013 Mar; 12(3):274-85. PubMed ID: 23053497
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endogenous Bak inhibitors Mcl-1 and Bcl-xL: differential impact on TRAIL resistance in Bax-deficient carcinoma.
    Gillissen B; Wendt J; Richter A; Richter A; Müer A; Overkamp T; Gebhardt N; Preissner R; Belka C; Dörken B; Daniel PT
    J Cell Biol; 2010 Mar; 188(6):851-62. PubMed ID: 20308427
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.